Letters
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 14 4071
L. Arylsulfonamidothiazoles as a new class of potential antidiabetic
drugs. Discovery of potent and selective inhibitors of 11ꢀ-hydroxys-
teroid dehydrogenase type 1. J. Med. Chem. 2002, 45, 3813–3815.
(5) Alberts, P.; Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.;
Norling, S.; Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.;
Nilsson, C. E.; Fiedler, M.; Bergqvist, E.; Ohman, B.; Jorkstrand, E.;
Abrahmsen, L. B. Selection inhibition of 11ꢀ-hydroxysteroid dehydro-
genase type 1 improves hepatic insulin sensitivity in hyperglycemic
mice strains. Endocrinology 2003, 144, 4755–4762.
(6) Walker, B. R.; Connacher, A. A.; Lindsay, M.; Webb, D. J.; Edwards,
C. R. W. Carbenoxolone increases hepatic insulin sensitivity in man: a
novel role for 11-oxosteroid reductase in enhancing glucocorticoid
receptor activation. J. Clin. Endocrinol. Metab. 1995, 80, 3155–3159.
(7) Kotelevtsev, Y. V.; Brown, R. W.; Fleming, S.; Kenyon, C.; Edwards,
C. R. W.; Seckl, J. R.; Mullins, J. Hypertension in mice lacking 11ꢀ-
hydroxysteroid dehydrogenase type 2. J. Clin. InVest. 1999, 103, 683–
689.
Figure 1. Serum insulin after 7 days of treatment.
(8) (a) Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in
metabolic disease and therapeutic potential of 11beta-HSD1 inhibitors.
Curr. Med. Chem. 2008, 15 (7), 642–649. (b) St. Jean, D. J.; Yuan, C.;
Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate,
R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch,
C. 2-(S)-Phenethylaminothiazolones as potent, orally efficacious inhibi-
tors of 11b-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 2007,
50, 429–432. (c) Xiang, J.; Ipek, M.; Suri, V.; Tam, M.; Xing, Y.;
Huang, N.; Zhang, Y.; Tobin, J.; Mansour, T.; McKew, J. ꢀ-Keto
sulfones as inhibitors of 11ꢀ- hydroxysteroid dehydrogenase type 1 and
the mechanism of action. Bioorg. Med. Chem. 2007, 15, 4396–4405.
(d) Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.;
Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.;
Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp,
H.; Frevert, E. U.; Jackbson, P.; Link, J. T. Adamantane sulfone and
sulfonamide 11-ꢀ-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2007,
17, 527–532. (e) Yeh, V.; Kurukulasuriya, R.; Madar, D.; Patel, J.;
Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham, H.;
Link, J. Synthesis and structural activity relationship of 11ꢀ-HSD1
inhibitors with novel adamantine replacements. Bioorg. Med. Chem.
Lett. 2006, 16, 5408–5413. (f) Schuster, D.; Maurer, E.; Laggner, C.;
Nashev, L.; Wilckens, T.; Langer, T.; Odermatt, A. The discovery of
new 11ꢀ- hydroxysteroid dehydrogenase type 1 inhibitors by common
feature pharmacophore modeling and virtual screening. J. Med. Chem.
2006, 49, 3454–3466. (g) Gu, X.; Dragovic, J.; Koo, G. C.; Koprak,
S. L.; LeGrand, C.; Mundt, S. S.; Shah, K.; Springer, M.; Tan, E.;
Thieringer, R.; Hermanowski-Vosatka, A.; Zokian, H.; Balkovec, J.;
Waddell, S. T. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as
potent and selective inhibitors of 11ꢀ-HSD1: novel therapeutic agents
for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett. 2005,
15, 5266–5269. (h) Olson, S.; Aster, S.; Brown, K.; Carbin, L.; Graham,
D.; Hermanowski, A.; LeGrand, C.; Mundt, S.; Robbins, M.; Schaeffer,
J.; Slossberg, L.; Szymonifka, M.; Thieringer, R.; Wright, S.; Balkovec,
J. Adamantyl triazoles as selective inhibitors of 11ꢀ-hydroxysteroid
dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359–4362.
(9) Xiang, J.; Saiah, E.; Tam, S.; McKew, J.; Chen, L.; Ipek, M.; Lee, K.;
Li, H. ; Li, J. ; Li, W.; Mansour, T.; Suri, V.; Vargas, R.; Wu, Y.;
Wan, Z.; Lee, J.; Binnun, E.; Wilson, D. 11-Beta HSD1 Inhibitors.
WO 092435, 2007.
induced hyperinsulinemia model. 13q and 13u led to decreased
insulin levels after 7 days of treatment via oral administration.
Acknowledgment. We thank Drs. Nelson Huang, Li Di, and
Walter Massefski for coordinating and obtaining analytical data,
Dr. Katherine Lee for editing the manuscript, and Dr. Steve
Tam for his scientific input.
Supporting Information Available: Experimental details for
the synthesis and characterization of all compounds. This material
References
(1) Gerstein, H. C.; Yusuf, S. Dysglycaemia and risk of cardiovascular
disease. Lancet 1996, 347, 949–950.
(2) (a) Tomlinson, J. W.; Walker, E. A.; Bujalska, I. J.; Draper, N.; Lavery,
G. G.; Cooper, M. S.; Hewison, M.; Stewart, P. M. 11ꢀ-Hydroxysteroid
dehydrogenase type 1: a tissue-specific regulator of glucocorticoid
response. Endocr. ReV. 2004, 25, 831–866. (b) Stulnig, T. M.;
Waldhausl, W. 11ꢀ-Hydroxysteroid dehydrogenase type 1 in obesity
and type 2 diabetes. Diabetologia 2004, 47, 1–11.
(3) (a) Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins,
J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity
and the metabolic syndrome. Science 2001, 294, 2166–2170. (b)
Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes,
M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without
obesity: hepatic overexpression of 11ꢀ-hydroxysteroid dehydrogenase
type 1 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2004, 101,
7088–7093. (c) Morton, N. M.; Paterson, M.; Masuzaki, H.; Holmes,
M.; Staels, B.; Fievet, C.; Walker, B.; Flier, J. S.; Mullins, J. J.; Seckl,
J. R. Novel adipose tissue-mediated resistance to diet-induced visceral
obesity in 11ꢀ-hydroxysteroid dehydrogenase type-1 deficient mice.
Diabetes 2004, 53, 931–938.
(4) Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.; Nygren,
A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom,
L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.; Abrahmsen,
JM8004948